FTRE
Fortrea Holdings Inc.
NASDAQ: FTRE · HEALTHCARE · BIOTECHNOLOGY
$10.56
-1.86% today
Updated 2026-04-29
Market cap
$998.82M
P/E ratio
—
P/S ratio
0.37x
EPS (TTM)
$-10.81
Dividend yield
—
52W range
$4 – $19
Volume
1.5M
Fortrea Holdings Inc. (FTRE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.58B | $3.06B | $2.84B | $2.84B | $2.70B | $2.72B |
| Revenue growth (YoY) | — | +18.5% | -7.2% | +0.2% | -5.1% | +1.0% |
| Cost of revenue | $2.09B | $2.45B | $2.11B | $2.25B | $2.16B | $2.30B |
| Gross profit | $489.10M | $604.40M | $724.40M | $590.60M | $534.20M | $425.80M |
| Gross margin | 19.0% | 19.8% | 25.5% | 20.8% | 19.8% | 15.6% |
| R&D | — | — | — | — | — | — |
| SG&A | $267.60M | $303.10M | $299.90M | $336.60M | $560.70M | $456.40M |
| Operating income | $-314.20M | $114.30M | $187.10M | $32.00M | $-161.90M | $-30.60M |
| Operating margin | -12.2% | 3.7% | 6.6% | 1.1% | -6.0% | -1.1% |
| EBITDA | $221.50M | $302.90M | $280.80M | $137.20M | $-64.30M | $-813.60M |
| EBITDA margin | 8.6% | 9.9% | 9.9% | 4.8% | -2.4% | -29.9% |
| EBIT | $102.50M | $136.60M | $187.20M | $39.20M | $-151.20M | $-891.60M |
| Interest expense | — | $200000.00 | $200000.00 | $69.80M | $123.80M | $91.40M |
| Income tax | $27.00M | $38.40M | $41.10M | $1.20M | $-3.50M | — |
| Effective tax rate | -8.1% | 28.2% | 18.1% | -5.0% | 1.1% | 0.0% |
| Net income | $-359.20M | $98.00M | $186.20M | $-25.20M | $-328.50M | $-986.20M |
| Net income growth (YoY) | — | +127.3% | +90.0% | -113.5% | -1203.6% | -200.2% |
| Profit margin | -13.9% | 3.2% | 6.6% | -0.9% | -12.2% | -36.2% |